GTF2H3

Across TCGA pan-cancer cohorts, GTF2H3 mass-spec protein differs between tumor and matched normal tissue in 5 of 18 cancer types tested, making tumor–normal expression one of GTF2H3’s most consistent transcriptional readouts.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where GTF2H3 mass-spec protein is more highly expressed in tumor relative to normal tissue. In most cancer types GTF2H3 is over-expressed in tumor, although a few such as COAD and PDAC show the opposite, repressed pattern.

HNSC, COAD, and LSCC are the cancer types where GTF2H3 tumor–normal differential expression is most reproducible.

mass-spec protein tumor vs normal associations by lineage

Ranked by sampling consensus. Fold-change is the tumor-versus-normal difference in GTF2H3 mass-spec protein (log₂); positive values indicate higher expression in tumor. p-values are from the differential-expression test.

Lineage	Gender	Stage	Fold-change	p	Sampling consensus
HNSC	Male	II,III,IV	+0.232	<.001	8	view →
COAD	All	All	−0.462	<.001	5	view →
LSCC	Male	II,III,IV	+0.209	<.001	5	view →
CCRCC	All	IV	+0.230	.032	3	view →
PDAC	Male	II,III,IV	−0.308	.009	2	view →

Pink = over-expressed in tumor, green = repressed in tumor. Showing the 5 strongest of 5 lineages.

GTF2H3–HNSC

Open the HNSC breakdown →